On April 27, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), reported it will take on the dual responsibilities of CSO and Chief Operating Officer (COO).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The promotion follows an internal management review of the optimal way of working to continue to deliver Evaxion’s strategy through broader external visibility of the power of the AI-Immunology platform with partners and investors. It also reflects the recognition of Dr Rønø’s long and extensive contribution to the internal operation of Evaxion over many years.
"I am delighted to announce the promotion of Dr Rønø to the dual role of CSO and COO, reflecting her long contribution to the efficient operation of the company coupled with her deep scientific expertise. Alongside the considerable expertise of the other members of the Evaxion management team, this change leaves us very well placed to continue building and broadening awareness of Evaxion’s unique AI capabilities in immune target discovery, vaccine and other drug product candidate design through to early preclinical and clinical validation," says Helen Tayton-Martin, CEO of Evaxion.
Following the promotion, Evaxion’s management team remains composed of the following members:
Helen Tayton-Martin, CEO
Birgitte Rønø, CSO and COO
Thomas Schmidt, CFO
Andreas Mattsson, Chief AI Officer
(Press release, Evaxion, APR 27, 2026, View Source [SID1234664791])